Patients with MG and vision loss may need screening for autoimmune retinopathy
Patients with myasthenia gravis who have vision problems should be screened for possible autoimmune retinopathy.
Patients with myasthenia gravis who have vision problems should be screened for possible autoimmune retinopathy.
The secretion of a protein known as BAFF by white blood cells contributes to the exacerbation of myasthenia gravis.
C-reactive protein was significantly associated with fatigue in MG.
Efgartigimod therapy showed notable efficacy in treating generalized myasthenia gravis.
Higher disease activity in myasthenia gravis leads to lower levels of quality of life.
Acetylcholinesterase inhibitors are a key tool for reducing symptoms in many patients with MG.
Researchers found that some patients with myasthenia gravis experience body image issues, which can depress quality of life.
Cemdisiran, an investigational therapy, showed promise in a phase 3 study assessing its use in managing generalized myasthenia gravis.
The eye muscles react differently to the immune system than other muscles, and are more likely to tire from use.
A study found that individuals with myasthenia gravis were more likely to also have diabetes mellitus.